Document is current
Any future updates will be listed below
-
Authors
van Mourik, Niels https://orcid.org/0000-0003-3826-4135
van Amstel, Rombout B. E.
Slim, Marleen A.
van Vught, Lonneke A.
van der Poll, Tom
Huckriede, Joram
de Vries, Femke
de Kimpe, Sjef J.
Crabbé, Raf
van Leeuwen, Simone J. M.
Ekhart, Peter F.
Reutelingsperger, Chris P. M.
Nicolaes, Gerry A. F.
Vlaar, Alexander P. J.
Müller, Marcella C. A.
-
Funding
Funding for this research was provided by:
Ministry of Economic Affairs/Health Holland (TKI PPP)
- License Information
-
More Information
Article History
Received: 24 December 2024
Accepted: 30 July 2025
First Online: 18 August 2025
Declarations
:
: The trial was approved by the Dutch Central Committee on Research Involving Human Subjects (CCMO; registration number: NL77116.000.21; date of approval: July 14, 2021) and the Dutch Ministry of Health, Welfare and Sport as competent authority. Written informed consent was required from patients or their legal representatives.
: Not applicable.
: SJdK, RC, SJMvL, and PFE are affiliated with Matisse Pharmaceuticals. CPMR and GAFN are advisors and shareholders of the company. TvdP serves on the scientific advisory board of Matisse Pharmaceuticals.
